Ken Griffin Scynexis Inc Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.27 - $2.23 $7,112 - $12,488	-5,600 Reduced 35.22%	10,300 $15,000
Q2 2024 Aug 14, 2024	BUY	$1.4 - $2.77 $22,260 - $44,043	15,900 New	15,900 $31,000
Q3 2023 Nov 14, 2023	SELL	$1.93 - $3.64 $35,512 - $66,976	-18,400 Reduced 92.46%	1,500 $3,000
Q2 2023 Aug 14, 2023	SELL	$2.38 - $3.67 $10,710 - $16,515	-4,500 Reduced 18.44%	19,900 $58,000
Q1 2023 May 15, 2023	SELL	$1.15 - $3.0 $11,270 - $29,400	-9,800 Reduced 28.65%	24,400 $73,000
Q4 2022 Feb 14, 2023	BUY	$1.46 - $2.94 $49,932 - $100,548	34,200 New	34,200 $53,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.